Innovative Psychiatry
FDA approves Spravato, a version of ketamine backed by Johnson & Johnson that sees rapid results in patients battling treatment resistant depression and suicide. HOUSTON, March 5, 2019 /PRNewswire/ — “New FDA approved depression treatment, esketamine, is the biggest advancement in depression treatment in thirty years” – says Houston based Psychiatrist, Dr. Sandhya Prashad. This approval allows ketamine treatments to be […]
The psychedelic revolution has arrived—yet psychologists still have major gaps in knowledge about going on a shrooms trip in the name of mental health. Michael Kuntz had been in talk therapy for a couple years, and felt stuck, like he wasn’t making progress on his anxiety or depression. “I found myself at a place where […]
Data Published from a Real World Psychiatry Practice Shows How Ketamine Infusions Can Avert ER Trips and Hospitalizations SOUTH WINDSOR, Conn., Oct. 8, 2019 /PRNewswire/ — Lori Calabrese, M.D., Innovative Psychiatry (https://www.loricalabresemd.com). Local psychiatrist publishes data demonstrating that the use of a series of IV ketamine infusions, with dose adjustments, can stop suicidal thoughts and avert ER trips […]
By Peggy McCarthy, Conn. Health I-Team Writer Published 11:51 am EDT, Tuesday, August 13, 2019 Some Connecticut hospitals and doctors and a clinic are starting to treat severely depressed patients with a new nasal spray called Spravato, touted as the most significant federally approved depression medication since Prozac was approved in 1987. Spravato, which received Food and Drug Administration […]
Spravato, which received Food and Drug Administration (FDA) approval in March, has raised hopes for preventing suicides and relieving depression after other treatments have failed. But there are concerns about possible side effects, including drug abuse, elevated blood pressure and heart rate, sedation, and hypersensitivity to surroundings. The nasal spray is prescribed for treatment-resistant depression after at […]
By Peggy McCarthy August 13, 2019 Originally published in Connecticut Health I-Team on C-Hit.org. Some Connecticut hospitals and doctors and a clinic are starting to treat severely depressed patients with a new nasal spray called Spravato, touted as the most significant federally approved depression medication since Prozac was approved in 1987. Spravato, which received Food and Drug Administration […]
In scientific journal letter, Hopkins psychiatrist Adam Kaplin disputes a study claiming ketamine is an opioid. Ketamine has gotten a bad reputation as an opioid—when there’s plenty of evidence suggesting it isn’t one, say Johns Hopkins experts. They believe this misconception may prevent patients from getting necessary treatment for the kinds of depression that don’t respond […]
Ketamine has gotten a bad rap as an opioid when there’s plenty of evidence suggesting it isn’t one, Johns Hopkins experts say. They believe this reputation may hamper patients from getting necessary treatment for the kinds of depression that don’t respond to typical antidepressants. In a new paper, the researchers clarify the mechanism behind ketamine’s […]
BY M. ALEXANDER OTTO REPORTING FROM APA 2019 SAN FRANCISCO – Serial ketamine infusions eliminated suicidal ideation in more than two-thirds of patients at a psychiatry office in Connecticut but at significantly higher doses than those recently approved for Janssen’s new esketamine nasal spray (Spravato). The patients were treated by Lori V. Calabrese, MD, at […]
A new study finds that a nasal spray formulated from the anesthetic ketamine is a safe, fast-acting and effective treatment for treatment-resistant depression. Researchers presented the findings this week at the annual meeting of the American Psychiatric Association. Esketamine, the intranasal formulation of ketamine, recently received FDA approval as a depression treatment when used with an oral antidepressant, based […]